These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26970965)

  • 21. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
    Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
    Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
    Tsao H; Goel V; Wu H; Yang G; Haluska FG
    J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
    Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
    Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic driver mutations in melanoma.
    Reddy BY; Miller DM; Tsao H
    Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
    Varada S; Mahalingam M
    Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
    Tate G; Tajiri T; Suzuki T; Mitsuya T
    Cancer Genet Cytogenet; 2009 Apr; 190(1):15-20. PubMed ID: 19264228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.
    Webster DE; Barajas B; Bussat RT; Yan KJ; Neela PH; Flockhart RJ; Kovalski J; Zehnder A; Khavari PA
    Genome Res; 2014 May; 24(5):751-60. PubMed ID: 24443471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent mutations in the MITF pathway in melanoma.
    Cronin JC; Wunderlich J; Loftus SK; Prickett TD; Wei X; Ridd K; Vemula S; Burrell AS; Agrawal NS; Lin JC; Banister CE; Buckhaults P; Rosenberg SA; Bastian BC; Pavan WJ; Samuels Y
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):435-44. PubMed ID: 19422606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
    Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
    Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance.
    Governa M; Caprarella E; Dalla Pozza E; Vigato E; Maritan M; Caputo GG; Zannoni M; Rosina P; Elefanti L; Stagni C; Menin C
    Melanoma Res; 2015 Oct; 25(5):443-6. PubMed ID: 26110554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal architectures and driver mutations in metastatic melanomas.
    Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
    PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
    Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.